title: Successful Treatment with an Antihypertensive Drug Regimen Including Eplerenone in a Patient with Malignant Phase Hypertension with Renal Failure.
abstract: A 28-year-old man was referred to our hospital for the treatment of congestive heart failure and severe hypertension. The patient was diagnosed with malignant phase hypertension based on the presence of marked hypertension with left ventricular hypertrophy, exudate retinopathy, and renal failure. Intensive therapy for hypertension and heart failure with a combination of antihypertensive drugs including nitroglycerin, nifedipine, eplerenone and candesartan successfully lowered his blood pressure and further improved the renal function. Eplerenone could be one of the choices of antihypertensive drugs in combination therapy in patients with malignant phase hypertension with progressive heart and renal failure.
authors.affiliation: Department of Cardiovascular Medicine, Rumoi City Hospital, Japan.
authors.forename: Fumihiko
authors.initials: F
authors.lastname: Takahashi
authors.forename: Masahide
authors.initials: M
authors.lastname: Goto
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Wada
authors.forename: Naoyuki
authors.initials: N
authors.lastname: Hasebe
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage; D000328:Adult; D000959:Antihypertensive Agents / Q000008:administration & dosage; D001562:Benzimidazoles / Q000008:administration & dosage; D001713:Biphenyl Compounds; D002121:Calcium Channel Blockers / Q000008:administration & dosage; D003404:Creatinine / Q000097:blood; D004359:Drug Therapy, Combination; D000077545:Eplerenone; D006333:Heart Failure / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D006974:Hypertension, Malignant / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D009543:Nifedipine / Q000008:administration & dosage; D005996:Nitroglycerin / Q000008:administration & dosage; D009765:Obesity / Q000097:blood / Q000150:complications* / Q000503:physiopathology; D051437:Renal Insufficiency / Q000097:blood / Q000188:drug therapy* / Q000517:prevention & control; D013148:Spironolactone / Q000008:administration & dosage / Q000031:analogs & derivatives; D013777:Tetrazoles / Q000008:administration & dosage; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000008:administration & dosage
chemical_list: D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D002121:Calcium Channel Blockers; D013777:Tetrazoles; D014665:Vasodilator Agents; D013148:Spironolactone; D000077545:Eplerenone; D003404:Creatinine; D005996:Nitroglycerin; D009543:Nifedipine; C081643:candesartan